Search

Displaying results 5361 - 5370 of 6831 in total
  1. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    to on normal cells. … SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II trials for cancer therapy.

  2. Drug

    Antipain

    go.drugbank.com/drugs/DB15251
    Experimental

    [A214490] The binding of antipain to OPB has been used in molecular dynamic studies to identify other OPB inhibitors with more favourable pharmacodynamic and pharmacokinetic properties for potential development … [A214481] Early studies investigated the potential for antipain to alter DNA damage and chromosomal aberrations in irradiated cells or those treated with chemical mutagens such as _N_-methyl-_N_'-nitro

  3. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    Covax-19™ was tested in animal studies, and shown to achieve potent antibody and T-cell responses against the COVID-19 spike protein. … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).

  4. Drug

    AVR-RD-01

    go.drugbank.com/drugs/DB17651
    Investigational

    AVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc.

  5. Drug

    Ginsenoside Rg1

    go.drugbank.com/drugs/DB06750
    ExperimentalNutraceutical

    Because ginsenosides appear to affect multiple pathways, their effects are complex and difficult to isolate. Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng).

  6. Drug

    Azosemide

    go.drugbank.com/drugs/DB08961
    Investigational

    Azosemide is a loop diuretic used to treat hypertension, edema, and ascites.

  7. Drug

    D-Lysine

    go.drugbank.com/drugs/DB03252
    Experimental

    It is often added to animal feed. [PubChem]

  8. Drug

    FT516

    go.drugbank.com/drugs/DB15732
    Investigational

    This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation.

  9. Drug

    Carbomycin

    go.drugbank.com/drugs/DB11383
    ExperimentalVet approved

    The structure of carbomycin was generated in 1957 by Robert Woodward and later modified in 1965.

  10. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978]